Danirixin

Drug Profile

Danirixin

Alternative Names: 1325756; GSK-1325756; GSK-1325756H; GSK1325756B

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antivirals; Piperidines; Sulfones
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Influenza virus infections

Most Recent Events

  • 15 Nov 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in USA (IV, Infusion)
  • 16 Oct 2017 GlaxoSmithKline initiates enrolment in a phase II trial for Chronic obstructive pulmonary disease in USA (PO)(NCT03170232)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top